General Information
Metacrine MET409-201
A Phase 2A Study to Evaluate MET409 Alone or in Combination with Empagliflozin in Patients with Type 2 Diabetes and Nonalcoholic Steatohepatitis.
| Protocol | MET409-201 |
|---|---|
| Identifier | |
| UID | c3ad8891-0a51-4dd2-89f1-c832e233af08 |
| Status | Done - Archived |
| Phase | 2 |
| Category | Fatty Liver / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2020-10-28 17:13 |
| Last Updated | 2020-10-28 17:13 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2021-05-21 | No |
| Enrollment Open | 2021-01-20 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2020-12-18 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2021-11-17 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Metacrine, Inc. |
|---|---|
| Division | Metacrine, Inc. |
| Team | Metacrine, Inc. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | ProSciento, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
